Compare Cytokinetics Inc (CYTK) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Devon Energy Corp — how do they compare? Cytokinetics Inc trades at $76.65 (market cap $10.63B), while Devon Energy Corp trades at $44.95 (market cap $49.94B). The key difference: Devon Energy Corp is far larger — about 4.7× Cytokinetics Inc's market cap, and Devon Energy Corp pays a 2.82% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | DVN | |
|---|---|---|
Market Cap | $10.63B | $49.94B |
Sector | Technology | Energy |
52-Week High | $87.26 | $52.07 |
52-Week Low | $34.31 | $31.74 |
Enterprise Value | $10.74B | $60.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Devon Energy (DVN) trades at $44.93, down 0.95% on the day, amid a bullish technical signal and strong Q2 2026 earnings that beat estimates. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil production. Valuation ratios remain attractive with a P/E of 9.87 and EV/EBITDA of 6.89. Recent news highlights a 33% dividend hike and accelerated debt reduction, reinforcing positive sentiment.
The outlook for DVN is positive, supported by robust free cash flow, shareholder returns, and operational execution. Key opportunities include synergy realization from the Coterra merger and a consensus price target of $61.91. Risks involve oil price volatility and integration challenges. Wall Street sentiment is strongly bullish with 71% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
